Activist investor Ananym is preparing a proxy fight at Henry Schein (HSIC), aiming to nominate directors to its board. An announcement about its Q4 2024 earnings release is scheduled, to be discussed further in a conference call and webcast. An optimistic forecast from Jefferies Financial Group suggests a potential increase for HSIC stock price. In other developments, Henry Schein completed the acquisition of Acentus, a key supplier of homecare medical supplies, a move that might contribute to the stock's upward trend. Meanwhile, the company has announced relief fund initiatives to counter effects from the California wildfires and the launch of an emergency support hotline. HSIC’s third-quarter earnings show promising metrics while its financial results led to an increased financial guidance for 2024. However, criticisms about the company’s returns on capital and the possible misalignment between its unclear financials and current share price momentum bear mention. The completion of the Acentus acquisition expands HSIC’s continuous glucose monitor portfolio. Based on Q3 Earnings estimates, Henry Schein is expected to perform well in the market.On a slightly concerning note, the recent sale of HSIC shares by insiders at the company alludes to possible weakness. Speculation of activist involvement sparked gains for Henry Schein and proposed changes from Ananym Capital show signs of a shakeup at HSIC.
Henry Schein HSIC News Analytics from Wed, 07 Feb 2024 08:00:00 GMT to Sat, 25 Jan 2025 18:17:09 GMT -
Rating 8
- Innovation 6
- Information 8
- Rumor 5
